R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)
- Status
- RECRUITING
- Phase
- PHASE2
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.
- Status
- UNKNOWN
- Phase
- N/A
A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV
- Status
- UNKNOWN
- Phase
- PHASE3
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients
- Status
- COMPLETED
- Phase
- PHASE2
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
DNA Vaccination Against Neuroblastoma
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
Biomarker Guided Treatment in DLBCL
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2